A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jun 2016
At a glance
- Drugs Cabergoline (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Therapeutic Use
- 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 03 Sep 2015 Planned End Date changed from 1 Jul 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 03 Sep 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.